Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS01.23.17
Over the past few years, Risk-Based Monitoring (RBM) – in which sponsors allocate monitoring resources based on the level of risk identified for a specific trial or site – has emerged as a more efficient way to facilitate trial delivery. RBM strategies optimize data flows, enhance data quality and improve oversight and control of clinical trial sites. And the benefits of RBM strategies have only just begun.
At the annual SCOPE Summit for Clinical Ops Executives, Rajneesh Patil, senior director, RBM and Analytics at QuintilesIMS is giving a presentation on Implementing Risk-Based Monitoring that will explore the future in this area, and how predicative analytics and machine learning are enabling a more holistic and proactive approach to identify and mitigate risk.
Rajneesh Patil of QuintilesIMS
Learning from the past
RBM relies on data and analytics to assess site performance, identify potential outliers and determine a
At the annual SCOPE Summit for Clinical Ops Executives, Rajneesh Patil, senior director, RBM and Analytics at QuintilesIMS is giving a presentation on Implementing Risk-Based Monitoring that will explore the future in this area, and how predicative analytics and machine learning are enabling a more holistic and proactive approach to identify and mitigate risk.
Rajneesh Patil of QuintilesIMS
RBM relies on data and analytics to assess site performance, identify potential outliers and determine a
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
